HANXBIO-B Buys Back 48,700 H Shares for HKD 1.40 Million; Treasury Stock Rises to 1.76 Million Shares

Bulletin Express07-03 19:44

Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“HANXBIO-B”) executed an on-market repurchase of 48,700 H shares on 3 July 2026, paying a total of HKD 1.40 million. The shares were bought at prices ranging from HKD 27.96 to HKD 28.96, translating into a volume-weighted average cost of HKD 28.68 per share.

Following the transaction: • Issued shares (excluding treasury shares) decreased 0.036 % to 134.46 million. • Treasury shares increased to 1.76 million. • Total issued share capital remained unchanged at 136.22 million.

The repurchase was made under the mandate approved on 24 June 2026, which permits the company to buy back up to 13.47 million shares. To date, 238,300 shares—equivalent to 0.18 % of the share base at mandate approval—have been repurchased.

Under Hong Kong Stock Exchange rules, HANXBIO-B is restricted from issuing new shares or disposing of treasury shares until 2 August 2026. The board confirms that all repurchase procedures complied with the Exchange’s regulations and relevant laws.

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap

Leave a comment

{"i18n":{"language":"en_US"},"isChannel":false,"data":{"share":"https://ttm.financial/m/news/1197069512?lang=en_US&edition=fundamental","thumbnail":"","is_english":true,"pubTime":"2026-07-03 19:44","share_image_url":"https://static.laohu8.com/e9f99090a1c2ed51c021029395664489","id":"1197069512","market":"hk","top_or_hot":-1,"title":"HANXBIO-B Buys Back 48,700 H Shares for HKD 1.40 Million; Treasury Stock Rises to 1.76 Million Shares","media":"Bulletin Express","content":"<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“HANXBIO-B”) executed an on-market repurchase of 48,700 H shares on 3 July 2026, paying a total of HKD 1.40 million. The shares were bought at prices ranging from HKD 27.96 to HKD 28.96, translating into a volume-weighted average cost of HKD 28.68 per share.</p>\n<p>Following the transaction:\n• Issued shares (excluding treasury shares) decreased 0.036 % to 134.46 million.  \n• Treasury shares increased to 1.76 million.  \n• Total issued share capital remained unchanged at 136.22 million.</p>\n<p>The repurchase was made under the mandate approved on 24 June 2026, which permits the company to buy back up to 13.47 million shares. To date, 238,300 shares—equivalent to 0.18 % of the share base at mandate approval—have been repurchased.</p>\n<p>Under Hong Kong Stock Exchange rules, HANXBIO-B is restricted from issuing new shares or disposing of treasury shares until 2 August 2026. The board confirms that all repurchase procedures complied with the Exchange’s regulations and relevant laws.</p>","source":null,"html":"<!DOCTYPE html>\n<html>\n<head>\n<meta http-equiv=\"Content-Type\" content=\"text/html; charset=utf-8\" />\n<meta name=\"viewport\" content=\"width=device-width,initial-scale=1.0,minimum-scale=1.0,maximum-scale=1.0,user-scalable=no\"/>\n<meta name=\"format-detection\" content=\"telephone=no,email=no,address=no\" />\n<title>HANXBIO-B Buys Back 48,700 H Shares for HKD 1.40 Million; Treasury Stock Rises to 1.76 Million Shares</title>\n<style type=\"text/css\">\na,abbr,acronym,address,applet,article,aside,audio,b,big,blockquote,body,canvas,caption,center,cite,code,dd,del,details,dfn,div,dl,dt,\nem,embed,fieldset,figcaption,figure,footer,form,h1,h2,h3,h4,h5,h6,header,hgroup,html,i,iframe,img,ins,kbd,label,legend,li,mark,menu,nav,\nobject,ol,output,p,pre,q,ruby,s,samp,section,small,span,strike,strong,sub,summary,sup,table,tbody,td,tfoot,th,thead,time,tr,tt,u,ul,var,video{ font:inherit;margin:0;padding:0;vertical-align:baseline;border:0 }\nbody{ font-size:16px; line-height:1.5; color:#999; background:transparent; }\n.wrapper{ overflow:hidden;word-break:break-all;padding:10px; }\nh1,h2{ font-weight:normal; line-height:1.35; margin-bottom:.6em; }\nh3,h4,h5,h6{ line-height:1.35; margin-bottom:1em; }\nh1{ font-size:24px; }\nh2{ font-size:20px; }\nh3{ font-size:18px; }\nh4{ font-size:16px; }\nh5{ font-size:14px; }\nh6{ font-size:12px; }\np,ul,ol,blockquote,dl,table{ margin:1.2em 0; }\nul,ol{ margin-left:2em; }\nul{ list-style:disc; }\nol{ list-style:decimal; }\nli,li p{ margin:10px 0;}\nimg{ max-width:100%;display:block;margin:0 auto 1em; }\nblockquote{ color:#B5B2B1; border-left:3px solid #aaa; padding:1em; }\nstrong,b{font-weight:bold;}\nem,i{font-style:italic;}\ntable{ width:100%;border-collapse:collapse;border-spacing:1px;margin:1em 0;font-size:.9em; }\nth,td{ padding:5px;text-align:left;border:1px solid #aaa; }\nth{ font-weight:bold;background:#5d5d5d; }\n.symbol-link{font-weight:bold;}\n/* header{ border-bottom:1px solid #494756; } */\n.title{ margin:0 0 8px;line-height:1.3;color:#ddd; }\n.meta {color:#5e5c6d;font-size:13px;margin:0 0 .5em; }\na{text-decoration:none; color:#2a4b87;}\n.meta .head { display: inline-block; overflow: hidden}\n.head .h-thumb { width: 30px; height: 30px; margin: 0; padding: 0; border-radius: 50%; float: left;}\n.head .h-content { margin: 0; padding: 0 0 0 9px; float: left;}\n.head .h-name {font-size: 13px; color: #eee; margin: 0;}\n.head .h-time {font-size: 11px; color: #7E829C; margin: 0;line-height: 11px;}\n.small {font-size: 12.5px; display: inline-block; transform: scale(0.9); -webkit-transform: scale(0.9); transform-origin: left; -webkit-transform-origin: left;}\n.smaller {font-size: 12.5px; display: inline-block; transform: scale(0.8); -webkit-transform: scale(0.8); transform-origin: left; -webkit-transform-origin: left;}\n.bt-text {font-size: 12px;margin: 1.5em 0 0 0}\n.bt-text p {margin: 0}\n</style>\n</head>\n<body>\n<div class=\"wrapper\">\n<header>\n<h2 class=\"title\">\nHANXBIO-B Buys Back 48,700 H Shares for HKD 1.40 Million; Treasury Stock Rises to 1.76 Million Shares\n</h2>\n\n<h4 class=\"meta\">\n\n\n<a class=\"head\" href=\"https://laohu8.com/wemedia/1053168898\">\n\n\n<div class=\"h-thumb\" style=\"background-image:url(https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e);background-size:cover;\"></div>\n\n<div class=\"h-content\">\n<p class=\"h-name\">Bulletin Express </p>\n<p class=\"h-time\">2026-07-03 19:44</p>\n</div>\n\n</a>\n\n\n</h4>\n\n</header>\n<article>\n<p>Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“HANXBIO-B”) executed an on-market repurchase of 48,700 H shares on 3 July 2026, paying a total of HKD 1.40 million. The shares were bought at prices ranging from HKD 27.96 to HKD 28.96, translating into a volume-weighted average cost of HKD 28.68 per share.</p>\n<p>Following the transaction:\n• Issued shares (excluding treasury shares) decreased 0.036 % to 134.46 million.  \n• Treasury shares increased to 1.76 million.  \n• Total issued share capital remained unchanged at 136.22 million.</p>\n<p>The repurchase was made under the mandate approved on 24 June 2026, which permits the company to buy back up to 13.47 million shares. To date, 238,300 shares—equivalent to 0.18 % of the share base at mandate approval—have been repurchased.</p>\n<p>Under Hong Kong Stock Exchange rules, HANXBIO-B is restricted from issuing new shares or disposing of treasury shares until 2 August 2026. The board confirms that all repurchase procedures complied with the Exchange’s regulations and relevant laws.</p>\n\n</article>\n</div>\n</body>\n</html>\n","isBrief":false,"type":0,"news_type":1,"symbol":"03378","symbol_name":"翰思艾泰-B","start_time":0,"source_url":"","article_id":"1197069512","we_media_id":"1053168898","thumbnails":[],"rights":null,"url":"https://stock-news.laohu8.com/highlight/detail?id=1197069512","pubTimestamp":1783079045,"columns":[],"sourceInfo":null,"weMediaInfo":{"media_name":"Bulletin Express","introduction":"Full Coverage of HK & US Stock Announcements","home_visible":1,"id":"1053168898","head_image":"https://community-static.tradeup.com/news/ed558ed0402cbe7d1ef4d150458f2b2e"},"summary":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“HANXBIO-B”) executed an on-market repurchase of 48,700 H shares on 3 July 2026, paying a total of HKD 1.40 million. The shares were bought at prices...","collect":0,"end_time":0,"defaultTopTitle":"","property":[],"viewcount":null,"language":"en","relate_stocks":{"03378":"翰思艾泰-B"},"translate_title":"汉思生物-B以140万港元回购4.87万股H股；库存股增至176万股","themeId":null,"isJumpTheme":false,"ttsUrl":null,"symbols_score_info":{"03378":1},"content_text":"Hanx Biopharmaceuticals (Wuhan) Co., Ltd. (“HANXBIO-B”) executed an on-market repurchase of 48,700 H shares on 3 July 2026, paying a total of HKD 1.40 million. The shares were bought at prices ranging from HKD 27.96 to HKD 28.96, translating into a volume-weighted average cost of HKD 28.68 per share.\nFollowing the transaction:\n• Issued shares (excluding treasury shares) decreased 0.036 % to 134.46 million.  \n• Treasury shares increased to 1.76 million.  \n• Total issued share capital remained unchanged at 136.22 million.\nThe repurchase was made under the mandate approved on 24 June 2026, which permits the company to buy back up to 13.47 million shares. To date, 238,300 shares—equivalent to 0.18 % of the share base at mandate approval—have been repurchased.\nUnder Hong Kong Stock Exchange rules, HANXBIO-B is restricted from issuing new shares or disposing of treasury shares until 2 August 2026. The board confirms that all repurchase procedures complied with the Exchange’s regulations and relevant laws.","kind":"news","is_publish_news":true,"is_publish_highlight":false,"is_publish_live":false,"is_publish_wemedia":true,"editions":null,"column":"","sentiment":"1","news_tag":"shareholding,SGX","news_rank":0,"isVideo":false,"video":null,"symbols":[],"gpt_button":0,"need_auth":false,"need_login_tip":false,"code":"91000000","status":"200"},"commentList":[],"isCommentEnd":true,"newsSizeData":{"likeSize":0,"commentSize":0,"repostSize":0,"favoriteSize":0,"likeStatus":false,"favoriteStatus":false},"APP":{"userAgent":"Mozilla/5.0 AppleWebKit/537.36 (KHTML, like Gecko; compatible; ClaudeBot/1.0; +claudebot@anthropic.com)","isDev":false,"isTTM":true,"isLaohu8Offline":false,"tenantId":"TBGLOBAL","deviceId":"web-server-community-laohu8-v3","version":"4.44.1","shortVersion":"4.44.1","platform":"web","vendor":"web","appName":"ttm","isIOS":false,"isAndroid":false,"isTiger":false,"isTHS":false,"isWeiXin":false,"isWeiXinMini":false,"isWeiBo":false,"isQQ":false,"isBaiduSwan":false,"isBaiduBox":false,"isDingTalk":false,"isToutiao":false,"isOnePlus":false,"isHuaWei":false,"isXiaomi":false,"isXiaomiWebView":false,"isOppo":false,"isVivo":false,"isSamsung":false,"isMobile":false},"href":"/m/news/1197069512","isCrawlerRequest":true}